Quarterly ResultMay 13, 2026, 08:37 AM
ANI Pharma Raises 2026 Guidance; Q1 Revenue +20%; $100M Buyback
AI Summary
ANI Pharmaceuticals reported strong Q1 2026 results, with total net revenues increasing 20% to $237.5 million and adjusted non-GAAP EBITDA rising 24% to $63.0 million. The company also raised its full-year 2026 financial guidance, projecting total net revenues of $1.08 billion to $1.14 billion and adjusted non-GAAP EBITDA of $285 million to $300 million. Additionally, the Board authorized a new $100 million share repurchase program and the company recognized a $15 million upfront license fee from an out-licensing deal with Harmony Biosciences.
Key Highlights
- Raised 2026 total net revenue guidance to $1.08B-$1.14B.
- Raised 2026 adjusted non-GAAP EBITDA guidance to $285M-$300M.
- Board authorized new $100M share repurchase program.
- Q1 2026 total net revenues increased 20% to $237.5M.
- Q1 2026 adjusted non-GAAP EBITDA rose 24% to $63.0M.
- Rare Disease business expected to represent ~60% of 2026 revenues.
- Cortrophin Gel net revenue projected $540M-$575M in 2026.
- Recognized $15M upfront license fee from Harmony Biosciences in Q1 2026.
Price Impact
More from ANIP